Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic compound platform for the treatment of a wide range of autoimmune diseases based on complement immunotherapy. Uncontrolled complement activation can lead to a variety of life-threatening or debilitating diseases. Apellis is the first company to advance chronic treatment with a C3 inhibitor into clinical trials. Apellis is currently evaluating its lead product candidate in a Phase 1b clinical trial for paroxysmal nocturnal hemoglobinuria and a Phase 2 clinical trial for geographic atrophy, an advanced form of dry age-related macular degeneration.